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Retinal gene therapy has come a long way in the last few decades and the development
and improvement of new gene delivery technologies has been exponential. The recent
promising results from the first clinical trials for inherited retinal degeneration due to
mutations in RPE65 have provided a major breakthrough in the field and have helped
cement the use of recombinant adeno-associated viruses (AAV) as the major tool for
retinal gene supplementation. One of the key problems of AAV however, is its limited
capacity for packaging genomic information to a maximum of around 4.8 kb. Previous
studies have demonstrated that homologous recombination and/or inverted terminal
repeat (ITR) mediated concatemerization of two overlapping AAV vectors can partially
overcome the size limitation and help deliver larger transgenes. The aim of this study
was to investigate and compare the use of different AAV dual-vector approaches in the
mouse retina using a systematic approach comparing efficiencies in vitro and in vivo
using a unique oversized reporter construct. We show that the hybrid approach relying
on vector genome concatemerization by highly recombinogenic sequences and ITRs
sequence overlap offers the best levels of reconstitution both in vitro and in vivo compared
to trans-splicing and overlap strategies. Our data also demonstrate that dose and vector
serotype do not affect reconstitution efficiency but a discrepancy between mRNA and
protein expression data suggests a bottleneck affecting translation.
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INTRODUCTION
Recently, the first ever adeno-associated virus (AAV) gene transfer therapeutic, Glybera R©, was
approved for commercialization in Europe for the treatment of familial lipoprotein lipase deficiency
(LPLD) (www.uniqure.com/). Long-term evaluation of this therapy showed a reduction in the
severity and incidence of pancreatitis (Gaudet et al., 2016). In the eye, advances in gene therapy
are marked by the successful outcomes of clinical trials for Leber Congenital Amaurosis (LCA)
(Bennett et al., 2016) and choroideremia (MacLaren et al., 2014). In these studies, patients had
improved and sustained retinal sensitivity and LCA patients also had improved navigation in
mobility tests under various light conditions, as a measure of how these treatments can improve
the quality of life for patients (MacLaren et al., 2014; Bennett et al., 2016). These are only three of
the 91 currently listed AAV mediated gene therapy clinical trials (https://clinicaltrials.gov/). The
large number of on-going trials highlights the impact that gene transfer has on changing the way
autosomal recessive diseases are treated.
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Some of the main reasons to employ AAV for clinical
therapies are that it has very low incidence of host genome
integration, is well tolerated in most tissues, and production
generates titer high enough to be used for humans (Ferreira
et al., 2014). However, one of the main limiting factors of
this strategy is the restriction of transgene size that can be
packaged into AAV, which is ∼4.8 kb (Wu et al., 2010). A
study by Wu et al. (2010) showed that packaged AAV genomes
never exceeded 5.2 kb in length, but overpackaging results in
genome fragmentation. It has also been shown that vectors
carrying larger genomes have lower transduction capacity, most
likely due to a preferential degradation of vectors encapsidating
larger genomes (Grieger and Samulski, 2005). Even though
protein expression from oversized AAV vectors with fragmented
genomes due to reconstitution of overlapping fragments has
been detected (Grieger and Samulski, 2005), use of heterogenous
fragmented vector preparations is not a feasible option in clinical
applications. As a result, developing vectors to treat many retinal
diseases, such as Usher’s Syndrome Type 2A, which is caused by
a mutation in a gene with a 15.8 kb coding region, is virtually
impossible. Moreover, regulatory sequences that may be required
to drive gene expression add to the final size and may render
many genes too large for AAV packaging. Consequently, there
is great interest in increasing transgene size while still utilizing
the AAV system and the use of a dual AAV vectors system has
been extensively studied for different experimental and disease
modalities (Chamberlain et al., 2016).
The dual method to increase the size of the gene delivered
to target cells consists in administering two separate gene
fragments within independent AAVs. For this approach to
work, the packaged transgenes must contain one of the
following: (1) overlapping sequences to allow for homologous
recombination, known as overlapping technique, (2) splice
acceptor (sA) and splice donor (sD) sequences for intermolecular
concatamerization and splicing in the trans-splicing technique,
or (3) a hybrid of both of the above using a highly
recombinogenic sequence known as the hybrid technique (Duan
et al., 2001). It has been shown that the fragments will reassemble
when transferred to a cell and produce a full-length protein
(Yan et al., 2000, 2002; Duan et al., 2003; Hirsch et al., 2009).
In the retina, the dual approach was first reported by Reich
et al. (2003) which used the trans-splice technique to show
that β-galactosidase expression in vivo was around 40% after
AAV5 subretinal injection (Reich et al., 2003). Furthermore, the
three dual approaches (trans-splicing, overlapping or “hybrid”
techniques) have been used to express the MYO7A and the
ABCA4 genes (both with CDS over 6 kb in length and expressed
in the retina) and showed effective in vitro protein expression
(Dyka et al., 2014). Different studies have also shown that these
dual AAV approaches are efficient at transducing mouse and pig
retinas, with the trans-splicing and hybrid systems being themost
efficient in vivo (Colella et al., 2014; Dyka et al., 2014; Trapani
et al., 2014, 2015).
Even though the dual AAV method feasibility has been
demonstrated by rescue of disease phenotype in different models,
a more fundamental understanding of vector reconstitution
efficiencies has been lacking. Furthermore, despite promising
results, the low efficiency of AAV dual strategies remains a
hurdle for further ocular translational applications, even when
using vectors with extremely high retinal transduction capacity
like AAV8. For this purpose, we generated a dual vector reporter
construct approach based on quantification of β-galactosidase
enzymatic activity, which offers better precision than
quantification based on western blot band intensity comparisons.
Further, an enzymatic assay identifies reconstitution based on
protein function, not just size, thus excluding potential incorrect
reconstitution events. Our aim in this study was to offer a more
systematic approach to dual strategy comparisons in vitro and
in vivo using a unique oversized reporter construct and to
test different variables that could be behind the low efficiency
reported when using AAV dual approaches.
MATERIALS AND METHODS
Constructs, Vectors, and AAV Production
The oversized Rainbow transgene construct was synthesized
by DNA2.0 (Newark, CA) and cloned into an ITR containing
plasmid. All dual left and right and control CMV.lacZ constructs
were then derived from the original oversized Rainbow with
extra features (sD and sA sites, AP sequence) added via PCR
and standard restriction enzyme cloning. AAV2/2, AAV2/8, and
AAV2/Anc80L65 for dual and control constructs were prepared
at Gene Transfer Vector Core (vector.meei.harvard.edu/) at
Massachusetts Eye and Ear Infirmary as previously described
(Zinn et al., 2015).
In Vitro Experiments
All in vitro experiments were performed on HEK293 cells
on poly-D-lysine-coated 6-well (Sigma, Natick, MA) plates
for plasmid transfections and 96-well plates (Sigma, Natick,
MA) for AAV transduction experiments. Cells were passaged
as standard and plasmid transfected with equal molarities
or AAV transduced at around 70% confluency. Transfection
experiments were done in triplicates with identical conditions
to ensure equal transfection efficiencies. AAV particles were
added directly to the cell media at the desired MOI while
plasmid transfection was performed using polyethylenimine
(Polysciences Inc., Warminster, PA). Cells were then incubated
for 48 h at 37◦C with 5% CO2 after which media was aspirated
and proceeded to β-galactosidase detection method as described
below in Section Protein Assay.
In Vivo Experiments
Wild-type C57BL/6J-Tyrc-2J/J male mice (6–8 weeks old) were
purchased from the Jackson Laboratory (Bar Harbor, ME) and
kept at the Schepens Eye Research Institute (SERI) Animal
Facility. All animal procedures were performed in accordance
with protocols approved by the institutional animal care and use
committees at SERI and conformed to the guidelines on the care
and use of animals adopted by the Association for Research in
Vision and Ophthalmology (Rockville, MD).
Subretinal Injections
Subretinal injections were performed by injecting 2 µl of vector
between the retinal pigment epithelium (RPE) and photoreceptor
layer by scleral tunnel approach, using theMicro4 injector system
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and 10 µl Nanofil syringe (World Precision Instruments, LLC.,
Sarasota, FL). For the combination of left (L) and right (R)
constructs (low dose group), viral genomes (vg) were diluted
together to generate a final titer of 1.5E12 vg/ml (total 3E9
vg/eye). For the high dose group, equal volumes of R and
L constructs were mixed together at the concentration of
1.5E13 vg/ml, which generated a final titer of 7.5E12 vg/ml
(1.5E10 vg/eye) of each construct. As a result, the “high dose”
group received 5 times more vg than the “low dose” group.
Monocistronic CMV.lacZ vectors were injected with half of total
L + R dose so that a theoretical 100% reconstitution would
result in identical full genome amounts as compared to control.
Finally, the left construct alone was injected at a concentration
of 1.5E12 vg/ml (3E9 vg/eye). Each separate experiment used
4–6 eyes per experimental group. Eyes were collected 4 weeks
post-injection for RNA or protein isolation by use of AllPrep
DNA/RNA/Protein kit (Qiagen, Hilden, Germany) or Galacto-
Light PlusTM System (Applied Biosystems, Foster City, CA),
respectively.
Real-Time PCR
Real-time PCR was performed in duplicate to quadruplicate
using the TaqMan R© gene expression master mix (Thermo
Fisher Scientific, Waltham, MA) on an ABI 7500 Real Time
PCR System (Applied Biosystems). RNA was isolated as
described above and reverse-transcribed using the QuantiTect
Reverse Transcription Kit (Qiagen). Relative transcript levels
were assessed using the 1CT method with GAPDH as
the reference gene (Taqman Assay Mm99999915_g1; Cat. #
4331182; Life Technologies, Woburn, MA). Primers used for
lacZ detection were the following (5′–3′): GATCAAATCTGT
CGATCCTTCC (forward) and GCGTACATCGGGCAAATAAT
(reverse) along with Universal Library probe #70 from Roche
(Basel, Switzerland). The lacZ primer/probe assay was specifically
designed to span the exact location where the lacZ gene is
split into left and right constructs in the dual hybrid strategy.
Real Time PCR figure presented represents the average of two
independent plates, each containing four eyes per group.
Protein Assay
Both in vivo and in vitro β-galactosidase quantification were
performed using the Galacto-Light PlusTM System (Applied
Biosystems) and a Synergy H1 Hybrid l Reader luminometer
plate reader (BioTek, Winooski, VT). In vitro experiments
followed the Direct Lysis Protocol for Microplate Cultures as
described by the manufacturer. In vivo experiments followed
a similar protocol but with the following modifications.
Whole retinas (minus RPE) were dissected from injected
eyes at 4 weeks post-injections and added to 100 µl of T-
PER Tissue Protein Extraction (Thermo Fisher Scientific) and
followed manufacturer’s protocol for protein extraction. Protein
extracts were then quantified using the standard protocol from
the Coomassie PlusTM (Bradford) Assay Kit (Thermo Fisher
Scientific) and 10 µg of total protein lysate was then used
for β-galactosidase quantification with the Galacto-Light PlusTM
System. Quantification of relative β-galactosidase levels in each
experiment was done by first subtracting from the raw values
a baseline measurement (from the same plate) of an R- or
L-only construct well/eye. These values were then normalized
to a CMV.lacZ construct of the same MOI/titer. Based on
our plasmid transfection experiments β-galactosidase expression
from Rainbow plasmids (original intact and hypothetical
reconstituted plasmids containing introns, as indicated in
Figure 1) was lower than from CMV-lacZ plasmid (Figure 2A).
Therefore, even 100% reconstitution efficiency of e.g., hybrid
DUO vectors could only result in 83.4% protein levels of CMV-
lacZ control. To account for this discrepancy all normalized
values were further divided by fold reduction in expression
of each respective control plasmid, as indicated by values in
Figure 2A.
Statistical Analysis
A two-tail student’s t-test was performed to analyze all data sets.
The data was considered significantly different when p < 0.01.
Error bars represent standard error mean (S.E.M.) or standard
deviation (S.D.) as indicated.
RESULTS
Generation of Dual Vector Reporter
Constructs
In order to evaluate the efficiency of dual AAV vector strategies,
we designed an oversized monocistronic multiple reporter
construct that would only allow expression of each and all of the
components following expected reconstitution of the oversized
cistron. The construct illustrated in Figure 1A comprised of
mCherry, lacZ, Gluc, and eGFP coding sequences separated
by furin-2A peptide cleavage sites. The full-length construct,
named pRainbow, is expressed from a CMV promoter and
translated into a single polypeptide which is subsequently
cleaved to separate the four reporter proteins. Dual vectors
were constructed by splitting pRainbow into two parts (left i.e.,
5′ and right i.e., 3′) within the lacZ sequence. Reconstitution
strategies were designed to rely on homologous recombination
based on sequence homology (overlap; OL), AAV splicing across
ITRs of a concatamerized dimeric genome (trans-splicing; TS),
and combination of the two (hybrid; HB) (Figure 1). Each
approach will result in reconstitution of transcriptionally active
Rainbow construct. OL constructs of three different lengths of
sequence homology within the lacZ gene were generated and
tested (1,100, 600, and 300 bp, data not shown). The construct
containing the largest homology sequence generated the best
reconstitution efficiency therefore was used hereafter (data not
shown). Figure 1E shows the different possible permutations for
TS constructs, highlighting the only combination that would lead
to correct genome reconstitution.
As neither left nor right constructs contains a full lacZ coding
sequence, correct reconstitution can be accurately quantified by
measuring the amount of its protein product, β-galactosidase,
with standard enzymatic assays. Since our interest was to
assess the relative efficiency of a dual AAV (OL, TS, or HB)
vs. the traditional single AAV approach, we first wanted to
account for the inherent difference in expression level due
to the distinct expression contexts for lacZ of the single
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FIGURE 1 | Schematic representation of dual AAV strategies with size of each left and right construct. (A) Oversized monocistronic Rainbow construct showing order
of reporter genes separated by furin-2A peptide cleavage sites. (B) Normal sized control construct (CMV.lacZ). (C) Overlap (OL) dual AAV strategy showing split left
and right constructs and reconstituted genome structure. (D) Hybrid (HB) dual AAV strategy (top) and the equivalent reconstituted genome structures underneath.
(E) Trans-splicing (TS) dual AAV strategy (top) and overview of the possible concatameric permutations for TS vectors with the highlighted combination (green box)
that would lead to a correctly reconstituted genome. OL-C, HB-C, and TS-C denominate the structure of the control plasmid used in Figure 2A.
vs. each of the dual AAV lacZ expression cassettes. Original
Rainbow sequence is anticipated to be restored only after OL
reconstitution, whereas TS will have an intron containing an
AAV ITR sequence, and HB will have an intron with AP or
AP-ITR-AP sequence (Figures 1D,E). Therefore, we measured β-
galactosidase expression from cells transfected with equimolar
amounts of plasmids coding for the different iterations of
reconstituted Rainbow plasmid constructs from OL, TS and
HB or CMV.lacZ coding control plasmid. The results show
that all possible Rainbow construct combinations are capable of
reconstituting with β-galactosidase levels between 70.6 and 83.4%
of the monocistronic CMV.lacZ control (Figure 2A), illustrating
that the lacZ expression from a Rainbow-type cassette was
high and only moderately decreased compared to an expression
cassette that expresses only lacZ, outside of the other reporter
genes. All protein expression data from dual vector reconstitution
efficiencies were normalized against CMV.lacZ controls at the
same MOI unless otherwise stated, and then corrected for β-
galactosidase levels using the respective plasmid control data
shown in Figure 2A as follows: OL transductions were divided by
0.74 (OL control, OL-C), HB were divided by 0.83 (HB control,
HB-C) and TS were divided by 0.71 (TS control, TS-C).
Reconstitution Efficiencies of Dual Vectors
in Vitro
Next, we compared efficiencies of different dual vector strategies
in vitro. HEK293 cells were transduced with left and right
AAV2/2 dual vectors and CMV.lacZ control vector. No β-
galactosidase was detected in cells transduced with left or right
vectors by themselves (data not shown). Total doses for dual
vector combinations were twice to control so that theoretical
maximum copy number of reconstituted Rainbow would be
equal to control. Based on β-galactosidase levels, reconstitution
efficiencies were 10.3, 15.3, and 17.4% of control for TS, HB, and
OL, respectively (Figure 2B). OL reconstitution is dependent on
overlapping sequence length, with shorter overlap showing lower
efficiencies (data no shown), and on the recombinogenic capacity
of this sequence, which is expected to be gene-dependent. As
such, the OL strategy would result in different reconstitution
efficiencies for every transgene. In contrast, reconstitution based
on uniform homologous sequences, such as in the hybrid
approach, should result in equal efficiencies regardless of the
transgene. Therefore, due to homology sequence-specificity and
undetectable in vivo reconstitution of OL vectors (Figure 3A),
further in vitro characterization was performed with HB
constructs only.
Effect of dose on reconstitution was studied by transducing
HEK293 cells with increasing amounts of HB dual vectors. The
data show moderately increasing levels of β-galactosidase (8.4%,
15.1% and 17.7% for 1E+7, 1E+8 and 1E+9 vg, respectively)
when compared to matching control doses (Figure 2C)
indicating increased co-transfection due to higher MOIs.
Further, increasing dual vector doses 10- and 100-fold (from 1E7
to 1E8 and 1E9) we see corresponding 18- and 103-fold increases
in β-galactosidase levels, respectively when compared to 1E7
control (Figure 2D).
Reconstitution Efficiency of Dual Vectors
in Vivo
Dual vector reconstitution efficiencies were evaluated
in vivo in the mouse retina. C57BL/6J-Tyrc-2J/J mice were
injected subretinally with AAV2/8 left and right dual vectors
combinations and control CMV.lacZ vectors. Total protein
was extracted from dissected retinas and β-galactosidase levels
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were measured. Reconstitution efficiencies were 9.07 and
1.78% of control for HB and TS, respectively (Figure 3A).
OL reconstitution efficiency (1,100 bp homology construct)
was below assay background level and is therefore not shown
(−0.67% ± SEM 0.54). Further in vivo experiments were only
FIGURE 2 | In vitro validation of dual AAV strategies. (A) Comparison of
expression levels of β-galactosidade from plasmid transfection of different
iterations of reconstituted Rainbow constructs (OL-C, HB-C, and TS-C) and
CMV.lacZ coding control plasmid (LacZ). Two tailed Student’s t-test was used
to determine significance compared to CMV.lacZ (*p < 0.01). Error bars
represent S.E.M. (B) In vitro efficiency comparison of AAV2 dual hybrid (HB),
trans-splice (TS) and overlap (OL) to monocistronic CMV.lacZ (LacZ) construct
of β-galactosidase protein expression. (C) Dose experiment comparison of
AAV2 HB dual constructs at three different doses (MOI of 1E7, 1E8, and 1E9)
with each dose relative to CMV.lacZ at the equivalent dose while (D) shows
expression levels of the three doses of HB relative to CMV.lacZ control at the
1E7 dose. In vitro data are represented as mean ± S.D. from 1 to 2 assays
done in triplicates and values are shown as percentage of control (CMV.lacZ)
after background subtraction (L construct only) and corrected for plasmid
reconstitution rates (using data from graph A).
performed with HB vectors, as it proved to be distinctly the most
efficient strategy.
Next, we studied the effects of capsid serotype on protein
reconstitution efficiency. We chose to compare AAV2/8 and
Anc80L65 vectors, as Anc80L65 has been shown to transduce
retinal cells with a higher efficiency than AAV8 (Zinn et al., 2015).
As shown in Figure 3A, retinal cell transduced with Anc80L65
had an almost identical level of HB reconstitution compared to
AAV8 (9.57%) even though a comparison of the absolute levels
of β-galactosidase from the control CMV.lacZ vector for each
serotype shows that Anc80L65 is 14-fold higher than AAV8 (data
not shown).
Our final experiment investigated reconstitution efficiency
and effect of vector dose on protein and mRNA levels
(Figures 3B,C). Interestingly mRNA levels (Figure 3B) showed
significantly higher rates of reconstitution than protein levels
(Figure 3C), however a 5-fold increase in vector dose only
resulted in 2.2- and 1.5-fold increases in mRNA and protein
levels, respectively. All mice injected with left construct alone
did not have LacZ expression as detected by the qPCR assay: CT
values “not determined” or 36.2+ (data not shown).
DISCUSSION
Gene replacement therapies utilizing AAV vectors have proven
their potential in treating several diseases with limited options
for alternate treatments. The first commercial AAV gene therapy
product has already seen the light of day (Gaudet et al.,
2016), and promising results from numerous ongoing clinical
trials may herald the emergence of other products in the near
future (Naldini, 2015; Pierce and Bennett, 2015). However,
despite its safety and efficacy as a gene therapy vector, AAV
has its shortcomings, one being the limited capacity of its
genetic payload (Kotterman and Schaffer, 2014). Even though,
in humans, the median protein size is only 375 amino acids
long (Grieger and Samulski, 2005), easily fitting into an AAV
vector with suitable elements for regulation of expression, several
important candidate genes for gene replacement therapies, such
FIGURE 3 | In vivo validation of dual AAV strategies. (A) In vivo comparison of dual strategies after subretinal injections using AAV8 or Anc80_L65 relative to AAV8
CMV.lacZ (LacZ) control at a dose of 3E9 vg/eye. (B) mRNA expression data comparing reconstituted genomes from HB at different doses (low: 3E9 vg/eye; high:
1.5E10 vg/eye). The delta-CT presented is normalized to GAPDH, relative to CMV.lacZ (LacZ). (C) Protein expression levels of HB in vivo at different doses (low: 3E9
vg/eye; high: 1.5E10 vg/eye). In vivo data are represented as mean ± S.E.M. from 2 to 3 assays done in duplicate to quadruplicate from 4 to 6 eyes per group.
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as USH2A (Usher syndrome type 2A), F8 (hemophilia A) or
DMD (Duchenne muscular dystrophy), are too large. Different
strategies to enable AAV gene therapies for larger genes have been
studied, including gene truncation, in vivo genome editing, and
use of dual AAV vectors. Each strategy comes with their own
potentials and problems.
Dual AAV vector strategies rely on rAAV genome
concatamerization utilizing ITRs and/or transgene cassette
sequence homologies. Vector reconstitution has been reported
in vitro in several cell lines, and in vivo in mouse liver, skeletal
muscle, and retina (Grieger and Samulski, 2005). Depending on
experimental details, in vivo efficiencies of∼5–10% as compared
to transgene expression from single AAV approaches have been
reported, and in some model systems this has resulted in rescue
of a disease phenotype, indicating that efficiencies with clinical
relevance can be achieved. However, even though dual AAV
vector strategies have been shown to work, details behind cellular
mechanisms underlying vector reconstitution are still poorly
understood. Despite the seemingly simple premise of dual AAV
strategies, there are several conceptual inefficiencies that could
affect reconstitution efficiency and would need to be overcome
when considering clinical applicability and broader applications.
These include not only general parameters that affect all dual
strategies, but also ones specific to each strategy. Amongst the
general issues, it is thought that (i) co-transduction efficiency
and (ii) efficiency of expressing a large transgene cassette, play
a major role in determining overall reconstitution levels and
need to be taken into consideration in the experimental design
(e.g., choice of serotype, expression system etc.). However, when
analyzing the different dual strategies, the parameters to consider
become substantially more complex. As we show in Figure 1E,
there are several different ways that the left and right vectors
from the TS approach could come together, which overall lowers
the probability of correct concatamerization and consequently
reconstitution efficiency. For both the OL and HB approaches,
the homology sequence will be critical in determining the
levels of reconstitution. In the OL strategies, sequences will be
gene-specific dependent with only a few variables like overlap
size and sequence optimization amenable to modifications. For
HB, however, the discovery of better homology sequences could
help improve reconstitution levels and efficiency.
Studies comprehensively comparing efficiencies of different
dual AAV vector strategies in the retina have been limited. Even
though vector reconstitution in the retina has been detected
for clinically relevant large transgenes, such as ABCA4 or
MYO7A, due to lack of proper controls (e.g., using oversized
monocistronic vectors) and accurate protein quantification
methods, determining parameters for clinical approaches has
been lacking (Dyka et al., 2014; Trapani et al., 2014, 2015).
Here, we compared efficiencies of commonly used dual vector
strategies (TS, OL and HB) in vivo in mouse retina using
an oversized ubiquitously expressed lacZ reporter construct.
Our reporter construct was designed with two main purposes;
(i) to provide an accurately quantifiable protein product and
(ii) to allow generation of normal sized monocistronic control
vectors. Functionality of our dual vectors and controls was
assessed in vitro, and showed that protein expression from
oversized reporter was similar to normal sized controls. When
reconstitution efficiencies based on protein expression were
quantified by normalizing lacZ expression levels to their
respective controls, levels of 15.3, 17.4, and 10.3% were detected
for HB, OL and TS, respectively. Interestingly, different relative
efficiencies have been reported by others, especially regarding
HB and TS (Dyka et al., 2014; Trapani et al., 2014). While all
designs seemingly use sequences originally reported by Ghosh
et al. (2008), the drastic differences in HB reconstitution within
AP intron sequence seen between the different studies, may
reflect undetected or unreported mutations between sequences,
especially in the ITRs, indicating sensitivity of reconstitution to
minor variations (Ghosh et al., 2008). We also studied whether
the effect of dose of dual vector transduction correlates linearly
with reporter transgene expression in vitro, and detected 17
and 102-fold increases in expression when dual vector dose
was increased 10 and 100-fold to controls, respectively. When
compared to controls of equal dose, reconstitution efficiencies
increased from 8.4 to 15.1 to 17.7% for doses of 1E7, 1E8,
and 1E9, respectively. The increase in efficiency likely reflects
increased vector co-transduction efficiency. However, at doses
of 1E8 and 1E9 co-transduction efficiency approaches 100%,
and the minor increase in reconstitution efficiency suggests that
reconstitution is not significantly dependent on intracellular
rAAV vector genome amounts.
Interestingly, our data indicates different relative efficiencies
of reconstitution in vivo in mouse retina with levels compared
to control, of 9.07% for HB, 1.78% for TS, and below detection
for OL. The drastic decrease in OL efficiency may reflect
differences in activities of pathways responsible of homologous
recombination in vivo as compared to in vitro. Even though
others have detected OL reconstitution in RPE cells, but not
photoreceptors, this may be due to differences in overlap lengths
and sequences (Trapani et al., 2015). Effect of serotype on vector
reconstitution was studied by comparing AAV8 and Anc80L65,
both of which transduce retinal cells with high efficiencies (Zinn
et al., 2015). Detected reconstitution efficiencies were similar.
Further, our in vivo dose escalation study only resulted in
moderate increase in protein levels. With similar observations
made from our in vitro dose escalation study, taken together these
data support our conclusion that once efficient co-transduction
is achieved, further increases in reconstitution efficiencies are not
strongly dependent of vector genome amounts. Therefore, these
studies may suggest an inherent limit for vector reconstitution
after dual AAV delivery. However, data from us and others also
indicates that these efficiencies depend on transgene sequences,
and may possibly be increased by using more recombinogenic
overlap and/or ITR sequences (Yan et al., 2005).
Surprisingly, our data revealed a major discrepancy between
levels of reconstituted protein and mRNA in vivo. While
reconstitution efficiency was assessed to be ∼10% based on
protein activity, mRNA amounts suggested ∼60% efficiency.
While our in vitro data supports ∼10% reconstitution efficiency,
as do earlier studies by others, the full story may be more
complicated. Both transcription and translation are strongly
affected by exact DNA and mRNA sequences, respectively, as
well as their cellular environments (Sonenberg and Hinnebusch,
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2009; Alpert et al., 2017). In particular, mRNA length has
been shown to negatively correlate with stability, which would
explain our observations (Feng and Niu, 2007). Assessing dual
AAV vector reconstitution quantitatively based on mRNA or
protein levels may thus be an inherently flawed approach,
as proper controls for these experiments are not feasible.
Rate of rAAV genome reconstitution may be quantifiable, but
resulting mRNA or protein levels are not, unless controls of
identical sequences are used. As dual AAVs are studied in
the context of oversized transgenes, oversized monocistronic
controls cannot be used. However, as being oversized is not
a prerequisite for use of dual vector strategies, mechanics
and efficiencies of vector reconstitution could also be studied
with transgenes that fit the AAV. Studies of this nature could
be informative in learning more about basic AAV biology,
and help design better dual vector strategies. For clinical
purposes, dual AAV approaches may be feasible if sufficient
protein expression levels to affect the disease phenotype can be
achieved, regardless of the de facto efficiency of the reconstitution
process.
An alternate method for expressing large proteins relying on
intein protein sequences has also been reported (Li et al., 2008;
Truong et al., 2015; Chew et al., 2016). In this approach, the
transgene is divided into two parts in which 5′ half of the gene
will express a C-terminal intein sequence, and 3′ half an N-
terminal intein sequence. Reconstitution will therefore take place
on peptide level in a process termed protein splicing, where
the intein sequences excise themselves and join the remaining
peptides together. Even though proof of concept studies have
shown feasibility of this approach, its efficiency has never been
thoroughly characterized. Further, proteins can be split by inteins
only at certain sites, and the reconstituted protein may not
reach proper conformation due to the two peptides folding
separately. Also, as the two peptides need to be expressed, both
vector halves will need their separate transcriptional regulators,
and with the added length of the intein sequences, gain of
payload carrying capacity is diminished as compared to genome
reconstitution approaches. Finally, inteins are of bacterial origin,
and as such may be immunogenic. However, despite these
drawbacks, intein mediated dual vector systems may warrant
further studies.
The in vivo aspect of this project focused on targeting the
retinal pigmented epithelium and the photoreceptor cells by
subretinal injection to maximize co-transduction efficiencies and
thus vector reconstitution. However, co-transduction can also
be achieved by intravitreal injection, which targets the retinal
ganglion cells and inner retina (Hung et al., 2016), albeit at
much lower efficiencies than by subretinal injections. With
the increasing focus on modified capsids to augment retinal
transduction, future experiments may employ an intravitreal
injection that can reach the photoreceptor cells, thereby reducing
the need for an invasive subretinal injection (Boye et al., 2016).
In conclusion, our work provides quantitative data on vector
reconstitution efficiencies in vivo in the retina. When targeting
retinal cells that are efficiently transduced by AAV, protein
expression levels of ∼10% of monocistronic vector levels may
be achieved. However, this may not be a reliable indicator of
actual reconstitution efficiency. Our work may offer insight on
developing improved dual vector approaches. As of now, dual
AAV vector strategies may be of use in gene therapy modalities
where even limited transgene expression has positive effects on
disease phenotype.
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